Prognostic Significance of Circulating MicroRNA-214 and -126 in Dogs with Appendicular Osteosarcoma Receiving Amputation and Chemotherapy

Overview

Journal BMC Vet Res

Publisher Biomed Central

Specialty Veterinary Medicine

Date 2019 Jan 27

PMID 30683101

Citations 12

Authors

Kazuki Heishima

Travis Meuten

Kyoko Yoshida

Takashi Mori

Douglas H Thamm

Affiliations

Soon will be listed here.

Abstract

Background: Dogs with appendicular osteosarcoma (OSA) receiving standard amputation and adjuvant chemotherapy demonstrate variable outcome with treatment; however, additional biomarkers would be helpful for predicting their outcome. In the present study, we assessed the potential of circulating microRNA-214 (miR-214) and - 126 (miR-126) to predict time to metastasis and death in dogs with OSA treated with amputation and chemotherapy.

Results: Seventy-six dogs that fully met inclusion criteria were included in the analysis. The criteria included (1) a diagnosis of appendicular OSA without metastases at diagnosis, (2) treatment by amputation and chemotherapy using carboplatin, doxorubicin, cisplatin, or a combination of these agents. Circulating miR-214 and -126 levels at the time before treatment were measured by using RT-qPCR. High circulating miR-214 and serum alkaline phosphatase (ALP) significantly predicted short disease-free survival (DFS) and overall survival (OS). Conversely, high circulating miR-126 significantly predicted prolonged DFS and OS. An integrated approach using circulating miR-214, - 126, and serum ALP showed better accuracy in the prediction of DFS and OS and identification of long-term survivors than prediction using only ALP. Other variables (age, weight, sex, monocyte counts, and primary tumor site) were associated with neither DFS nor OS. miRNA levels did not strongly correlate with histopathological indices.

Conclusions: Circulating miR-214, - 126, and an integrated prognostic score have strong potential to predict the outcome of canine appendicular OSA patients receiving amputation and chemotherapy.

Citing Articles

Plasma microRNA signatures predict prognosis in canine osteosarcoma patients.

Ludwig L, Edson M, Treleaven H, Viloria-Petit A, Mutsaers A, Moorehead R PLoS One. 2024; 19(12):e0311104.

PMID: 39739708 PMC: 11687810. DOI: 10.1371/journal.pone.0311104.

Review of Molecular Technologies for Investigating Canine Cancer.

Kehl A, Aupperle-Lellbach H, de Brot S, van der Weyden L Animals (Basel). 2024; 14(5).

PMID: 38473154 PMC: 10930838. DOI: 10.3390/ani14050769.

A review on microRNA detection and expression studies in dogs.

Varvil M, Dos Santos A Front Vet Sci. 2023; 10:1261085.

PMID: 37869503 PMC: 10585042. DOI: 10.3389/fvets.2023.1261085.

Circulating and extracellular vesicle-derived microRNAs as biomarkers in bone-related diseases.

Huber J, Longaker M, Quarto N Front Endocrinol (Lausanne). 2023; 14:1168898.

PMID: 37293498 PMC: 10244776. DOI: 10.3389/fendo.2023.1168898.

Blood biomarkers for canine cancer, from human to veterinary oncology.

Colombe P, Beguin J, Benchekroun G, Le Roux D Vet Comp Oncol. 2022; 20(4):767-777.

PMID: 35815441 PMC: 9796515. DOI: 10.1111/vco.12848.

References

Song Y, Li D, Guan Y, Wang Y, Zheng J . miR-214 modulates cisplatin sensitivity of osteosarcoma cells through regulation of anaerobic glycolysis. Cell Mol Biol (Noisy-le-grand). 2017; 63(9):75-79. DOI: 10.14715/cmb/2017.63.9.14. View

Heishima K, Ichikawa Y, Yoshida K, Iwasaki R, Sakai H, Nakagawa T . Circulating microRNA-214 and -126 as potential biomarkers for canine neoplastic disease. Sci Rep. 2017; 7(1):2301. PMC: 5442106. DOI: 10.1038/s41598-017-02607-1. View

Xu J, Liu P, Si M, Ding X . MicroRNA-126 inhibits osteosarcoma cells proliferation by targeting Sirt1. Tumour Biol. 2013; 34(6):3871-7. DOI: 10.1007/s13277-013-0974-x. View

Schmidt Y, Simunovic F, Strassburg S, Pfeifer D, Stark G, Finkenzeller G . miR-126 regulates platelet-derived growth factor receptor-α expression and migration of primary human osteoblasts. Biol Chem. 2014; 396(1):61-70. DOI: 10.1515/hsz-2014-0168. View

Mirabello L, Troisi R, Savage S . Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009; 115(7):1531-43. PMC: 2813207. DOI: 10.1002/cncr.24121. View

Straw R, Powers B, Klausner J, Henderson R, Morrison W, McCaw D . Canine mandibular osteosarcoma: 51 cases (1980-1992). J Am Anim Hosp Assoc. 1996; 32(3):257-62. DOI: 10.5326/15473317-32-3-257. View

Zhu X, Zhang Z, Han G, Han J, Qiu D . Overexpression of miR‑214 promotes the progression of human osteosarcoma by regulating the Wnt/β‑catenin signaling pathway. Mol Med Rep. 2017; 15(4):1884-1892. DOI: 10.3892/mmr.2017.6203. View

Heishima K, Mori T, Sakai H, Sugito N, Murakami M, Yamada N . MicroRNA-214 Promotes Apoptosis in Canine Hemangiosarcoma by Targeting the COP1-p53 Axis. PLoS One. 2015; 10(9):e0137361. PMC: 4559432. DOI: 10.1371/journal.pone.0137361. View

Schott C, Tatiersky L, Foster R, Wood G . Histologic Grade Does Not Predict Outcome in Dogs with Appendicular Osteosarcoma Receiving the Standard of Care. Vet Pathol. 2017; 55(2):202-211. DOI: 10.1177/0300985817747329. View

10.

Wang X, Sun J, Fu C, Wang D, Bi Z . MicroRNA-214 regulates osteosarcoma survival and growth by directly targeting phosphatase and tensin homolog. Mol Med Rep. 2014; 10(6):3073-9. DOI: 10.3892/mmr.2014.2616. View

11.

Bergman P, MacEwen E, Kurzman I, Henry C, Hammer A, Knapp D . Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993). J Vet Intern Med. 1996; 10(2):76-81. DOI: 10.1111/j.1939-1676.1996.tb02031.x. View

12.

Bartel D . MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281-97. DOI: 10.1016/s0092-8674(04)00045-5. View

13.

Turchinovich A, Weiz L, Langheinz A, Burwinkel B . Characterization of extracellular circulating microRNA. Nucleic Acids Res. 2011; 39(16):7223-33. PMC: 3167594. DOI: 10.1093/nar/gkr254. View

14.

Wang Z, Cai H, Lin L, Tang M, Cai H . Upregulated expression of microRNA-214 is linked to tumor progression and adverse prognosis in pediatric osteosarcoma. Pediatr Blood Cancer. 2013; 61(2):206-10. DOI: 10.1002/pbc.24763. View

15.

Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A . The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med. 2004; 10(2):182-6. DOI: 10.1038/nm982. View

16.

Jiang L, He A, Zhang Q, Tao C . miR-126 inhibits cell growth, invasion, and migration of osteosarcoma cells by downregulating ADAM-9. Tumour Biol. 2014; 35(12):12645-54. DOI: 10.1007/s13277-014-2588-3. View

17.

Jiang L, He A, He X, Tao C . MicroRNA-126 enhances the sensitivity of osteosarcoma cells to cisplatin and methotrexate. Oncol Lett. 2016; 10(6):3769-3778. PMC: 4665207. DOI: 10.3892/ol.2015.3790. View

18.

Spodnick G, Berg J, Rand W, Schelling S, Couto G, Harvey H . Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978-1988). J Am Vet Med Assoc. 1992; 200(7):995-9. View

19.

Garzotto C, Berg J, Hoffmann W, Rand W . Prognostic significance of serum alkaline phosphatase activity in canine appendicular osteosarcoma. J Vet Intern Med. 2000; 14(6):587-92. DOI: 10.1892/0891-6640(2000)014<0587:psosap>2.3.co;2. View

20.

Mullins M, Lana S, Dernell W, Ogilvie G, Withrow S, Ehrhart E . Cyclooxygenase-2 expression in canine appendicular osteosarcomas. J Vet Intern Med. 2005; 18(6):859-65. DOI: 10.1892/0891-6640(2004)18<859:ceicao>2.0.co;2. View